Safety and Cumulative Incidence of Major Cardiovascular Events with Ticagrelor in Taiwanese Patients with Non-ST-Segment Elevation Myocardial Infarction: A 12-Month, Prospective, Phase IV, Multicenter, Single-Arm Study

BACKGROUND: Ticagrelor, an oral, direct-acting, and reversible P2Y(12) receptor antagonist, inhibits platelet activation and aggregation. This phase IV, single-arm study analyzed the safety and tolerability of ticagrelor in Taiwanese patients with non-ST-segment elevation myocardial infarction (NSTE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Cardiol Sin
Hlavní autoři: Mar, Guang-Yuan, Ridderstråle, Wilhelm, Wei, Jianxin, Liu, Chun-Peng
Médium: Artigo
Jazyk:Inglês
Vydáno: Taiwan Society of Cardiology 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7220962/
https://ncbi.nlm.nih.gov/pubmed/32425434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6515/ACS.202005_36(3).20191007B
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky